Related Experiment Video

Updated: May 5, 2026

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

16.5K

Expression of CD45RO on circulating CD19+ B-cells in Crohn's disease

B R Yacyshyn1, L M Pilarski

  • 1Department of Medicine, University of Alberta, Edmonton, Canada.

Gut
|December 1, 1993
PubMed

Insights

Patients with Crohn's disease exhibit advanced B-cell differentiation in the gut and blood, indicated by CD45 isoform expression. This finding correlates with disease activity, suggesting a role for these differentiated B-cells in Crohn's pathogenesis.

Area of Science:

  • Immunology
  • Gastroenterology
  • Cell Biology

Background:

  • Crohn's disease is an intestinal immunoregulatory disorder with systemic effects.
  • B-cell differentiation antigens are key to understanding immune cell subsets.
  • CD45 isoform expression serves as a marker for B-cell maturation stages.

Purpose of the Study:

  • To identify unique B-cell subpopulations in Crohn's disease patients.
  • To analyze CD45 isoform expression as an indicator of B-cell differentiation.
  • To correlate B-cell differentiation markers with clinical parameters in Crohn's disease.

Main Methods:

  • Analysis of CD45 isoform expression on B-cells from blood and gut tissue.
  • Flow cytometry to identify B-cell subpopulations (CD19+).
  • Multiple regression analysis to correlate CD45 isoform expression with clinical data, including Crohn's Disease Activity Index (CDAI).

Main Results:

  • B-cells in Crohn's disease patients show advanced differentiation stages (transitional RA+RO+ and late-stage RO+) in the gut lamina propria, unlike healthy controls (primarily CD45RA+).
  • Heightened CD45RO isoform expression was observed on CD19+ lamina propria lymphocytes and a significant proportion of peripheral blood mononuclear cells (PBMCs) in Crohn's patients.
  • A statistically significant difference in CD45RO expression on CD19+ B-cells was found between patients with high and low CDAI.

Conclusions:

  • B-cells in Crohn's disease patients are characterized by an advanced differentiation state.
  • The expression pattern of CD45 isoforms on B-cells, particularly CD45RO, is altered in Crohn's disease.
  • CD45RO expression on B-cells correlates with Crohn's disease activity, suggesting its potential as a biomarker.

More Related Videos

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry07:39

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

Published on: January 7, 2019

11.7K
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.5K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.6K
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
35